SCHEMBL6005654

SCHEMBL6005654

CCCCOC(=O)C(C)=Cc1ccc(F)c(F)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPA1 O75762 3/20 0.50
▸ APP P05067 4/20 0.41
▸ GABRA1 P14867 1/20 0.39
▸ SIGMAR1 Q99720 1/20 0.39
▸ TUBB1 Q9H4B7 1/20 0.39
▸ ESR1 P03372 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ DNM1 Q05193 2/20 0.38
▸ TP53 P04637 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6005652 1.00 TRPA1 (0.50) TRPA1APPGABRA1SIGMAR1TUBB1
SCHEMBL7045919 0.90 ESR1 (0.41) TRPA1APPTUBB1ESR1KDM4E
SCHEMBL8175422 0.90 ESR1 (0.41) TRPA1APPTUBB1ESR1KDM4E
SCHEMBL25577505 0.86 TRPA1 (0.55) TRPA1GABRA1SIGMAR1TUBB1TSHR
SCHEMBL5607649 0.80 ESR1 (0.54) APPESR1KDM4ETSHRTDP1
SCHEMBL28989664 0.79 PLA2G4A (0.45) APPKDM4ETSHRTDP1L3MBTL1
SCHEMBL27463291 0.79 CYP1A2 (0.46) APPKDM4ETDP1ALDH1A1LMNA
SCHEMBL8702266 0.79 KDM4E (0.53) KDM4ETSHRTDP1L3MBTL1TP53
SCHEMBL2532167 0.79 KDM4E (0.53) KDM4ETSHRTDP1L3MBTL1TP53
SCHEMBL12056203 0.77 TUBB1 (0.43) TRPA1TUBB1ESR1ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105509-B2 Benzodiazepine derivatives as APP modulators MERCK SHARP & DOHME LIMITED (GB) 2006-09-12 — — US disclosed
US-20040082572-A1 Benzodiazepine derivatives as app modulators MERCK SHARPE & DOHME LIMITED (GB) 2004-04-29 — — US disclosed
EP-1294702-A1 BENZODIAZEPINE DERIVATIVES AS APP MODULATORS MERCK SHARP & DOHME LTD. (GB) 2003-03-26 — — EP disclosed
WO-2001090084-A1 BENZODIAZEPINE DERIVATIVES AS APP MODULATORS MERCK SHARP & DOHME LIMITED (GB) 2001-11-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082572-A1 Benzodiazepine derivatives as app modulators BACE1, PSEN1, APP TRPA1 1023/4885APP 3/4885GABRA1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback